Analyzing TearLab (TEAR) & Its Competitors

TearLab (OTCMKTS: TEAR) is one of 104 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its rivals? We will compare TearLab to similar companies based on the strength of its institutional ownership, profitability, analyst recommendations, valuation, earnings, dividends and risk.

Analyst Recommendations

How to Become a New Pot Stock Millionaire

This is a breakdown of current ratings and price targets for TearLab and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TearLab 0 0 2 0 3.00
TearLab Competitors 493 1873 3733 112 2.56

TearLab currently has a consensus price target of $4.00, suggesting a potential upside of 1,423.81%. As a group, “Surgical & medical instruments” companies have a potential upside of 14.48%. Given TearLab’s stronger consensus rating and higher possible upside, equities analysts clearly believe TearLab is more favorable than its rivals.

Valuation & Earnings

This table compares TearLab and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
TearLab $27.12 million -$16.10 million -0.10
TearLab Competitors $1.54 billion $111.98 million -141.70

TearLab’s rivals have higher revenue and earnings than TearLab. TearLab is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares TearLab and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TearLab -59.38% N/A -83.24%
TearLab Competitors -62.22% -47.34% -18.24%

Risk & Volatility

TearLab has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500. Comparatively, TearLab’s rivals have a beta of 0.80, suggesting that their average share price is 20% less volatile than the S&P 500.

Insider & Institutional Ownership

15.5% of TearLab shares are held by institutional investors. Comparatively, 48.0% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 12.0% of TearLab shares are held by insiders. Comparatively, 16.3% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

TearLab beats its rivals on 7 of the 13 factors compared.

TearLab Company Profile

TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.

Receive News & Ratings for TearLab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Cara Therapeutics  Receives $25.18 Consensus Target Price from Analysts
Cara Therapeutics Receives $25.18 Consensus Target Price from Analysts
Brokerages Set Tallgrass Energy Partners LP  Price Target at $48.67
Brokerages Set Tallgrass Energy Partners LP Price Target at $48.67
Amarin Co.  Expected to Post Earnings of -$0.07 Per Share
Amarin Co. Expected to Post Earnings of -$0.07 Per Share
Etheroll  Trading Up 58.5% Over Last 7 Days
Etheroll Trading Up 58.5% Over Last 7 Days
Contrasting TransMontaigne  & Shell Midstream Partners
Contrasting TransMontaigne & Shell Midstream Partners
Analyzing Superior Uniform Group  & Lululemon Athletica
Analyzing Superior Uniform Group & Lululemon Athletica


Leave a Reply

© 2006-2018 Ticker Report. Google+.